Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

13.2K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.2K
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

323
Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
323
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.6K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.6K
Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.5K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical evaluation of ex vivo expanded MUC1-specific peripheral blood T Cells for adoptive immunotherapy in relapsed/refractory multiple myeloma.

Cancer research communications·2026
Same author

Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination Survey.

Blood cancer journal·2026
Same author

Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers.

Blood cancer journal·2026
Same author

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Blood advances·2026
Same author

Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel.

Blood advances·2026
Same author

Tunneling Nanotube-Mediated Filamin A Transport Mechanosensitively Programs Osteoclastogenesis in Myeloma Bone Disease.

Blood·2026
Same journal

BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

Blood cancer discovery·2026
Same journal

Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma.

Blood cancer discovery·2026
Same journal

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Blood cancer discovery·2026
Same journal

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same journal

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026
Same journal

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026
See all related articles

Related Experiment Video

Updated: Oct 16, 2025

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.1K

Promiscuous Structural Variants Drive Myeloma Initiation and Progression.

P Leif Bergsagel1, W Michael Kuehl2

  • 1Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona.

Blood Cancer Discovery
|October 18, 2021
PubMed
Summary
This summary is machine-generated.

This study reveals that structural genomic variants, particularly involving the immunoglobulin heavy chain and MYC loci, drive multiple myeloma initiation and progression. It also uncovers numerous genomic factors contributing to the disease's complexity.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Related Experiment Videos

Last Updated: Oct 16, 2025

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.1K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Area of Science:

  • Genomics
  • Cancer Biology
  • Hematology

Background:

  • Multiple myeloma is a hematologic malignancy characterized by genomic complexity.
  • Understanding structural variants is crucial for elucidating disease mechanisms.

Purpose of the Study:

  • To conduct a comprehensive genomic analysis of structural variants in multiple myeloma.
  • To identify key genomic alterations and mechanisms contributing to disease heterogeneity.

Main Methods:

  • Genomic analysis of structural variants.
  • Identification of genomic hotspots, oncogenes, and tumor suppressor genes.
  • Investigation of recombination mechanisms.

Main Results:

  • Structural variants involving the immunoglobulin heavy chain locus are critical for multiple myeloma initiation.
  • Alterations at the MYC locus are associated with disease progression.
  • Multiple myeloma exhibits significant genomic heterogeneity due to numerous contributing factors.

Conclusions:

  • Structural genomic events play a pivotal role in multiple myeloma pathogenesis.
  • The complexity of multiple myeloma arises from a combination of genomic hotspots, oncogenes, tumor suppressor genes, and recombination mechanisms.